ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005044

hypertensive disorder

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. hypertensive disorder. Diseases, record MONDO_0005044. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005044

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
hypertensive disorder
Open Targets
Open Targets ID
MONDO_0005044
Open Targets
Other names
(hypertensive disease) or (hypertension), Arterial hypertension, Blood Pressures, High, HTN, HTN - hypertension, High Blood Pressures, High blood pressure (& [essential hypertension]), Hypertension, Hypertensive disease (disorder), Hypertensive disease NOS (disorder), SURG COMP - HYPERTENSION, Systemic hypertension, [X]Hypertensive diseases, [X]Hypertensive diseases (disorder), blood pressure, high, blood pressure, increased, high blood pressure, hyperpiesia, hypertension NOS, hypertensive disease, hypertensive disease NOS, increased blood pressure, pressure, high blood, vascular hypertensive disorder
Open Targets
Disease Ontology
DOID:10763
Disease Ontology
MeSH
D006973
MeSH
NCI Thesaurus
C3117
NCI Thesaurus
Highest stage of its drugs
Approval, for 187 of its 417 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs417

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
AMLODIPINECHEMBL1491Small moleculeApprovalEMA Human Drugs and TTD241229220Drugs and targets
HYDROCHLOROTHIAZIDECHEMBL435Small moleculeApprovalDailyMed, EMA Human Drugs, PMDA and TTD415165163Drugs and targets
VALSARTANCHEMBL1069Small moleculeApprovalDailyMed, EMA Human Drugs, PMDA and TTD217122121Drugs and targets
TELMISARTANCHEMBL1017Small moleculeApprovalDailyMed, EMA Human Drugs, PMDA and TTD155110107Drugs and targets
ALISKIRENCHEMBL1639Small moleculeApprovalEMA Human Drugs and TTD766666Drugs and targets
LOSARTANCHEMBL191Small moleculeApprovalPMDA and TTD696658Drugs and targets
NEBIVOLOLCHEMBL434394Small moleculeApprovalTTD464545Drugs and targets
CHLORTHALIDONECHEMBL1055Small moleculeApprovalDailyMed and TTD693535Drugs and targets
OLMESARTAN MEDOXOMILCHEMBL1200692Small moleculeApprovalDailyMed, PMDA and TTD583434Drugs and targets
NIFEDIPINECHEMBL193Small moleculeApprovalDailyMed743232Drugs and targets

1 to 10 of 417

See all 417 drugs

Targets246

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ADRB1Adrenergic receptor29
Adrenergic receptor agonist; Adrenergic receptor antagonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist; Beta-1 adrenergic receptor partial agonist
Approvalhttps://conductscience.org/library/genes/153Drugs and targets
CACNA1CVoltage-gated L-type calcium channel24Voltage-gated L-type calcium channel blockerApprovalhttps://conductscience.org/library/genes/775Drugs and targets
CACNA1DVoltage-gated L-type calcium channel24Voltage-gated L-type calcium channel blockerApprovalhttps://conductscience.org/library/genes/776Drugs and targets
CACNA1FVoltage-gated L-type calcium channel24Voltage-gated L-type calcium channel blockerApprovalhttps://conductscience.org/library/genes/778Drugs and targets
CACNA1SVoltage-gated L-type calcium channel24Voltage-gated L-type calcium channel blockerApprovalhttps://conductscience.org/library/genes/779Drugs and targets
ACEAngiotensin-converting enzyme23Angiotensin-converting enzyme inhibitorApprovalhttps://conductscience.org/library/genes/1636Drugs and targets
AGTR1Type-1 angiotensin II receptor21Type-1 angiotensin II receptor agonist; Type-1 angiotensin II receptor antagonistApprovalhttps://conductscience.org/library/genes/185Drugs and targets
ADRB2Adrenergic receptor18Adrenergic receptor agonist; Adrenergic receptor antagonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor partial agonistApprovalhttps://conductscience.org/library/genes/154Drugs and targets
ADRA1DAdrenergic receptor17
Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist; Alpha-1d adrenergic receptor antagonist
Approvalhttps://conductscience.org/library/genes/146Drugs and targets
ADRA1AAdrenergic receptor16Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonistApprovalhttps://conductscience.org/library/genes/148Drugs and targets

1 to 10 of 246

See all 246 targets

Trials1,037

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 20 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT02211638Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」18,1132018-11-05HypertensionCANDESARTAN CILEXETILIts record names the diseaseClinicalTrials.gov
NCT01454583Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany15,3372014-08-22Arterial HypertensionALISKIRENIts record names the diseaseClinicalTrials.gov
NCT02166697Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"14,1512016-07-11HypertensionCANDESARTAN CILEXETILIts record names the diseaseClinicalTrials.gov
NCT02092025Azilsartan Tablets Special Drug Use Surveillance: Long-term Use3,4372019-01-15HypertensionAZILSARTANIts record names the diseaseClinicalTrials.gov
NCT02068495Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"3,4092018-07-26HypertensionAMLODIPINE BESYLATE, CANDESARTAN CILEXETILIts record names the diseaseClinicalTrials.gov
NCT00749775Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)3,3382014-01-08HypertensionEPLERENONEIts record names the diseaseClinicalTrials.gov
NCT02016183Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)3,2222018-11-09HypertensionCANDESARTAN CILEXETIL, HYDROCHLOROTHIAZIDEIts record names the diseaseClinicalTrials.gov
NCT01137474A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor BlockerPhase 32,9962014-05-01Type 2 DiabetesDAPAGLIFLOZINIts record names the diseaseClinicalTrials.gov
NCT00890084Telmisartan Tab Hypertension2,9132012-05-02HypertensionHYDROCHLOROTHIAZIDE, TELMISARTANIts record names the diseaseClinicalTrials.gov
NCT00923091Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in HypertensionPhase 32,6892012-04-06Essential HypertensionAMLODIPINE, HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMILIts record names the diseaseClinicalTrials.gov

1 to 10 of 1,037

See all 1,037 trials

Comparisons in its trials305

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Caduet vs Usual Care: serious adverse events51 of 77922 of 6821,461NCT00407537Trial comparisons
Telmisartan 40mg and Amlodipine 10mg vs Telmisartan 80mg and Amlodipine 10mg: serious adverse events4 of 83813 of 6111,449NCT00624052Trial comparisons
Telmisartan 40mg and Amlodipine 5mg vs Telmisartan 80mg and Amlodipine 5mg: serious adverse events22 of 9766 of 3971,373NCT00614380Trial comparisons
Without Concomitant Drugs vs With Concomitant Drugs: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs.3 of 36015 of 8851,245NCT01107743Trial comparisons
Male vs Female: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender.7 of 45811 of 7871,245NCT01107743Trial comparisons
Without Hypertension vs With Hypertension: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension.0 of 818 of 1,2371,245NCT01107743Trial comparisons
Without Hypercholesterolemia vs With Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia.
0 of 1818 of 1,2271,245NCT01107743Trial comparisons
Without Complications vs With Complications: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications.5 of 56813 of 6771,245NCT01107743Trial comparisons
<65 Years vs >=65 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age.5 of 37713 of 8681,245NCT01107743Trial comparisons
Without Angina Pectoris vs With Angina Pectoris: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris.18 of 1,0620 of 1831,245NCT01107743Trial comparisons

1 to 10 of 305

See all 305 comparisons in its trials

Papers from its trials699

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
41052782RESULT1PubMed
39948072RESULT1PubMed
37907796RESULT1PubMed
37675576RESULT1PubMed
37534363RESULT1PubMed
37405785RESULT1PubMed
36369026RESULT1PubMed
36316628RESULT1PubMed
35686330RESULT1PubMed
34838503RESULT1PubMed

1 to 10 of 699

See all 699 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005044

GET https://conductscience.org/api/diseases/v1/MONDO_0005044/drugs?page=2

API referenceFor AI assistants